{
  "denotations": [
    {
      "id": "T1",
      "obj": "Disease",
      "span": {
        "begin": 5,
        "end": 10
      }
    },
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 22,
        "end": 39
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 74,
        "end": 77
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 82,
        "end": 88
      }
    },
    {
      "id": "T5",
      "obj": "Disease",
      "span": {
        "begin": 159,
        "end": 163
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "15188667_7",
  "text": "Most GISTs respond to imatinib mesylate , which selectively inhibits both KIT and PDGFRA , and is now considered as the standard systemic therapy for advanced GIST ."
}
